TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2368149
Drug: Double therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double therapy (cyclosporine and steroids)
Study: 2368149
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy (cyclosporine in lower initial dose, azathioprine, and steroids)
Study: 99235
Drug: IV hyperalimentation
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV hyperalimentation (IVH) administered before and after the first course of CIA for a total of 31 days
Study: 28464887
Drug: SBIRT Condition
Approvals — FDA: no, EMA: no, PMDA: no
Description: SBIRT Condition with face-to-face, tailored counseling focusing on child's illness, reducing child SHSe, caregiver smoking cessation, and nicotine replacement therapy option.
Study: 26120056
Drug: Continuous morphine
Normalized name: morphine sulfate Oral Suspension [MST Continus]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous morphine infusion (10 μg/kg/h)
Study: 24930359
Drug: Varenicline (titrated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Varenicline (titrated up to 1 mg)
Study: 21818622
Drug: Intravenous injection
Normalized name: Meta Trace FDG, intravenous injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous injection of 50 U/Kg of rHuEPO
Study: 17764013
Drug: Boswellia serrata
Normalized name: Boswellia Serrata
DrugBank: Indian frankincense (DB14275)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Boswellia serrata extract (BSE) 400 mg three times daily for 6 weeks
Study: 17764013
Drug: Open-label BSE
Normalized name: strontium chloride, 89Sr-labeled
DrugBank: Strontium chloride Sr-89 (DB09498)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Open-label BSE therapy
Study: 15226088
Drug: Vitamin E
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin E (alpha-tocopherol acetate, 400 mg/day)
Study: 9818751
Drug: Cefepime 2
Normalized name: cefepime 2000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefepime 2 g bd
Study: 9818751
Drug: Imipenem‐cilastatin 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imipenem‐cilastatin 1 g tds (50 mg/kg/day)
Study: 8110569
Drug: 5% EMLA
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% EMLA cream 2.5 g for 30 min
Study: 8110569
Drug: 5% EMLA
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% EMLA cream 2.5 g for 60 min
Study: 8110569
Drug: amethocaine cream
DrugBank: Tetracaine (DB09085)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: amethocaine cream 1 g (5% w/w) for 30 min
Study: 8110569
Drug: amethocaine cream
DrugBank: Tetracaine (DB09085)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: amethocaine cream 1 g (5% w/w) for 60 min
Study: 23733232
Drug: Alphacypermethrin (ACYP)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alphacypermethrin (ACYP) pour-on treatment
Study: 20066735
Drug: Probiotic mixture
Normalized name: brown mixture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic mixture of Bifidobacterium longum (BB536) and Lactobacillus johnsonii (La1) at a dose of 10^9, given orally 2 doses/day for 3 days preoperatively and continued postoperatively from day 2 to day 4
Study: 20066735
Drug: Probiotic mixture
Normalized name: brown mixture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic mixture of Bifidobacterium longum (BB536) and Lactobacillus johnsonii (La1) at a dose of 10^7, given orally 2 doses/day for 3 days preoperatively and continued postoperatively from day 2 to day 4
Study: 20066735
Drug: Placebo, given
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, given orally 2 doses/day for 3 days preoperatively and continued postoperatively from day 2 to day 4
Study: 20066735
Drug: Probiotic mixture
Normalized name: brown mixture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic mixture of Bifidobacterium longum (BB536) and Lactobacillus johnsonii (La1) at a dose of 10^9
Study: 19363849
Drug: Fixed combination
Normalized name: Progestogens and estrogens, fixed combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed combination of perindopril-indapamide
Study: 19648155
Drug: 0 ng
Normalized name: ALCOHOL 80 ng in 100 mL TOPICAL SPRAY [PSR Hand Sanitizer]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 ng ml(‐1) remifentanil
Study: 19648155
Drug: 2 ng
Normalized name: VITAMIN A ACETATE 700 ug / THIAMINE MONONITRATE 1 mg / RIBOFLAVIN 1 mg / NIACINAMIDE 12 mg / PYRIDOXINE HYDROCHLORIDE 1.15 mg / CYANOCOBALAMIN 3.5 ug / LEVOMEFOLATE CALCIUM 250 ug / ASCORBIC ACID 70 mg / CHOLECALCIFEROL 12 ng / .ALPHA.-TOCOPHEROL ACETATE, D- 11.5 mg / SODIUM FLUORIDE 1 mg ORAL TABLET [FloraFol]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 ng ml(‐1) remifentanil
Study: 19648155
Drug: 4 ng
Normalized name: NG
DrugBank: Nitroglycerin (DB00727)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 ng ml(‐1) remifentanil
Study: 11566624
Drug: iNOS specific
Normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
Approvals — FDA: no, EMA: no, PMDA: no
Description: iNOS specific inhibitors
Study: 11566624
Drug: Neutralising anti-TNF-alpha
Normalized name: anti-interleukin-1.alpha. immunoglobulin G rabbit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neutralising anti-TNF-alpha monoclonal antibody
Study: 8181202
Drug: Cotinine (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cotinine (30 mg) intravenously
Study: 3651943
Drug: One-dose regimen
Normalized name: Next Choice One Dose
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: One-dose regimen of trivalent inactivated whole-virion influenza vaccine (0.5 ml, containing 15 micrograms of hemagglutinin of each antigen)
Study: 3651943
Drug: Two-dose regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two-dose regimen of trivalent inactivated whole-virion influenza vaccine (0.5 ml, second dose administered 8 weeks after the first)
Study: 29990851
Drug: Propofol (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol (2 mg/kg) based on total body weight (TBW)
Study: 29990851
Drug: Propofol (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol (2 mg/kg) based on lean body weight (LBW)
Study: 26116635
Drug: Physical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical therapy (kinesitherapy and electrotherapeutic procedures) including medicamentous therapy, walking exercises beyond the pain threshold, dynamic low‐burden kinesi exercises, interference therapy, diadynamic therapy, and electromagnetic field.
Study: 26116635
Drug: Conventional non‐operative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional non‐operative treatment including medicamentous therapy and walking exercises.
Study: 17488793
Drug: rhGH (0.46
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhGH (0.46 mg/kg.wk) in daily sc injections
Study: 17488793
Drug: No rhGH
Approvals — FDA: no, EMA: no, PMDA: no
Description: No rhGH therapy
Study: 15061962
Drug: Propofol (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol (1.5 mg/kg, 2 mg/kg, and 3 mg/kg)
Study: 15061962
Drug: Midazolam (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam (0.2 mg/kg, 0.3 mg/kg, and 0.4 mg/kg)
Study: 15061962
Drug: Etomidate (0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etomidate (0.15 mg/kg, 0.3 mg/kg, and 0.4 mg/kg)
Study: 9745140
Drug: Micanol monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Micanol monotherapy
Study: 9745140
Drug: Micanol in
Approvals — FDA: no, EMA: no, PMDA: no
Description: Micanol in combination with UVB phototherapy
Study: 20127530
Drug: Central neuraxial
Normalized name: Rauwolfia alkaloids, centrally acting antiadrenergic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Central neuraxial blockade (anesthetic dose)
Study: 20127530
Drug: Central neuraxial
Normalized name: Rauwolfia alkaloids, centrally acting antiadrenergic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Central neuraxial blockade (analgesic dose)
Study: 18716414
Drug: Fluoxetine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine (20 mg) and folic acid (10 mg/day) for 6 weeks
Study: 18716414
Drug: Fluoxetine and
Normalized name: fluoxetine and psycholeptics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine and placebo for 6 weeks
Study: 12455569
Drug: Erythropoietin (EPO)
Normalized name: Erythropoietin
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythropoietin (EPO) therapy 6,000 U/week for 6 months
Study: 25040164
Drug: Clinic control
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clinic control (CC)
Study: 17785672
Drug: Brivaracetam 10,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brivaracetam 10, 20, 40, or 80 mg
Study: 17785672
Drug: Brivaracetam 80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brivaracetam 80 mg
Study: 15553820
Drug: hormone replacement
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: hormone replacement therapy (HRT)
Study: 10207795
Drug: Interferon therapy
Normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon therapy (10 MU/m2 of lymphoblastoid interferon alfa 3 times per week for 12 weeks)
Study: 2205259
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of 5-fluorouracil (5-FU) and plasma perfusion (PP) over protein A-Sepharose (group A)
Study: 2037387
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of 5-FU and PP over sepharose (group B)
Study: 31634603
Drug: Pharmacomechanical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacomechanical therapy
Study: 29733435
Drug: Imarikiren 80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imarikiren 80 mg (nonelderly)
Study: 29733435
Drug: Imarikiren 160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imarikiren 160 mg (nonelderly)
Study: 29733435
Drug: Imarikiren 80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imarikiren 80 mg (elderly)
Study: 23452670
Drug: Volumetric arc
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Volumetric arc therapy (VMAT)
Study: 20975107
Drug: Dextrose meal
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dextrose meal (2.25 g/kg)
Study: 20975107
Drug: Maltodextrin meal
Normalized name: Maltodextrin
DrugBank: Maltodextrin (DB12583)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maltodextrin meal (2.25 g/kg)
Study: 14634942
Drug: 4 mL
Normalized name: ethanol 1.4 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mL bupivacaine 0.5%
Study: 14634942
Drug: 4 mL
Normalized name: ethanol 1.4 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mL saline 0.9%
Study: 10390665
Drug: granisetron 40
Normalized name: Granisetron
DrugBank: Granisetron (DB00889)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: granisetron 40 mg kg‐1
Study: 10390665
Drug: perphenazine 70
Normalized name: Perphenazine
DrugBank: Perphenazine (DB00850)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: perphenazine 70 mg kg‐1
Study: 8877766
Drug: Adenine arabinoside
Normalized name: Adenine
DrugBank: Adenine (DB00173)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adenine arabinoside 5'‐monophosphate (ARA‐AMP), 5 mg/kg/day during 7 weeks
Study: 6357595
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg epirizole for 14 days
Study: 6357595
Drug: 3000 mg
Normalized name: talc 3000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3000 mg ASA
Study: 6357595
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg epirizole
Study: 2859465
Drug: Calcium bis
Normalized name: calcium bis(3-phenylpyruvate)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium bis acetyl homotaurine (Ca AOTA, 25 mg/kg/day)
Study: 31088531
Drug: Video intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Video intervention therapy (VIT) consisting of four modules with one video-recorded play session and one VIT session per week.
Study: 31088531
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as usual plus weekly play sessions (Control group).
Study: 22482940
Drug: Gemtuzumab ozogamicin
Normalized name: Gemtuzumab Ozogamicin
DrugBank: Gemtuzumab ozogamicin (DB00056)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Gemtuzumab ozogamicin (3 mg/m² on days 1, 4, and 7 during induction and day 1 of each of the two consolidation chemotherapy courses)
Study: 18929703
Drug: Aggressive lovastatin
Normalized name: Lovastatin
DrugBank: Lovastatin (DB00227)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aggressive lovastatin treatment (LDL cholesterol target <85 mg/dl)
Study: 18929703
Drug: Moderate lovastatin
Normalized name: Lovastatin
DrugBank: Lovastatin (DB00227)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Moderate lovastatin treatment (LDL cholesterol target <140 mg/dl)
Study: 8641743
Drug: Bendrofluazide 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bendrofluazide 5 mg once daily
Study: 1298186
Drug: SIN-1 (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: SIN-1 (1 mg)
Study: 10232493
Drug: Isosorbide dinitrate
Normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isosorbide dinitrate (5 mg)
Study: 6237916
Drug: Nicorandil 15
Normalized name: nicorandil
DrugBank: Nicorandil (DB09220)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicorandil 15 mg
Study: 6237916
Drug: Nicorandil 30
Normalized name: nicorandil
DrugBank: Nicorandil (DB09220)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicorandil 30 mg
Study: 20093512
Drug: Isosorbide dinitrate
Normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isosorbide dinitrate (ISDN) 5 mg
Study: 27009317
Drug: Dialectical behavior
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dialectical behavior therapy skills training
Study: 17150247
Drug: Doxorubicin and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxorubicin and cisplatin treatment in Stage III/IV patients with BMI ≥ 40
Study: 17150247
Drug: Doxorubicin and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxorubicin and cisplatin treatment in patients with higher BMI
Study: 17150247
Drug: Doxorubicin and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxorubicin and cisplatin treatment
Study: 16398437
Drug: Acupoint electro-superconducting
Normalized name: ELECTRODE SPRAY,ELECTRO MIST
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupoint electro-superconducting therapy with Chinese herbal drugs contained pad
Study: 12480356
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg single-dose mifepristone
Study: 12480356
Drug: 1.5 mg
Normalized name: boron 1.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 mg single-dose levonorgestrel
Study: 12480356
Drug: Two doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two doses of 0.75 mg levonorgestrel given 12 hours apart
Study: 9892860
Drug: Apomorphine (0.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apomorphine (0.75 mg s.c.)
Study: 27067836
Drug: Andrew's manoeuvre
Approvals — FDA: no, EMA: no, PMDA: no
Description: Andrew's manoeuvre (four-hands CC) during DA-CPR
Study: 25902891
Drug: Naloxone, opioid,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naloxone, opioid, and saline admixture (NOSA) containing 12 μg naloxone per 1 mg morphine per 1 mL normal saline.
Study: 25902891
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group receiving morphine only.
Study: 14550427
Drug: Levofloxacin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levofloxacin (500 mg/day) for 6 weeks
Study: 28806348
Drug: Vitamin E
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin E 200 mg/day
Study: 9165857
Drug: Home support
Approvals — FDA: no, EMA: no, PMDA: no
Description: Home support from a trained oncology nurse during treatment
Study: 9165857
Drug: Visits after
Approvals — FDA: no, EMA: no, PMDA: no
Description: Visits after treatment
Study: 3927958
Drug: Nicardipine 40
Normalized name: niCARdipine 40 mg/200 mL-D5% intravenous solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicardipine 40 mg thrice daily
Study: 31945816
Drug: GCWB104 (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: GCWB104 (300 mg containing 125 mg of Flos Lonicera extract, twice daily)
Study: 31945816
Drug: Placebo (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (300 mg, twice daily)
Study: 30293770
Drug: LY3298176 (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: LY3298176 (1 mg)
Study: 30293770
Drug: LY3298176 (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: LY3298176 (5 mg)
Study: 30293770
Drug: LY3298176 (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: LY3298176 (10 mg)
Study: 30293770
Drug: LY3298176 (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: LY3298176 (15 mg)
Study: 17975386
Drug: Early renal
Normalized name: Sus scrofa renal pelvis preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early renal replacement therapy
Study: 24998258
Drug: Delayed renal
Normalized name: nirmatrelvir
DrugBank: Nirmatrelvir (DB16691)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Delayed renal replacement therapy
Study: 7848024
Drug: Losartan 100
Normalized name: LOSARTAN 100MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan 100 mg once daily
Study: 21088400
Drug: Relaxin (intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Relaxin (intravenous doses)
Study: 19029516
Drug: Subcutaneous IGF-1
Normalized name: VEXXON-IGF-1
DrugBank: Mecasermin (DB01277)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Subcutaneous IGF-1 (0.05 mg/kg body weight, twice daily)
Study: 10827388
Drug: Local delivery
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local delivery of 5000 U heparin infused into the arterial wall
Study: 10827388
Drug: Intraluminal delivery
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraluminal delivery of 5000 U heparin administered to the coronary artery lumen
Study: 8846277
Drug: Patient Controlled
Normalized name: PATIENT CONTROLLED ANALGESIA VIAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient Controlled Analgesia (PCA) using morphine
Study: 24996988
Drug: Continuous morphine
Normalized name: morphine sulfate Oral Suspension [MST Continus]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous morphine infusion
Study: 8198941
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg kg‐1 intravenous lignocaine
Study: 8198941
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg kg‐1 intravenous lignocaine (fed)
Study: 8198941
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg kg‐1 intravenous lignocaine (fasted)
Study: 3332678
Drug: Topical benzyl
Normalized name: benzyl alcohol Topical Lotion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical benzyl alcohol (BA)
Study: 26358690
Drug: Apixaban 10
Normalized name: Apixaban
DrugBank: Apixaban (DB06605)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Apixaban 10 mg oral dose
Study: 23587538
Drug: Standardized uterosacral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standardized uterosacral ligament suspension colpopexy (USLSC)
Study: 26860492
Drug: Placebo ultrasound
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo ultrasound therapy
Study: 19494795
Drug: NGX-4010 capsaicin
Normalized name: Capsaicin
DrugBank: Capsaicin (DB06774)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: NGX-4010 capsaicin patch (640 microg/cm2) applied for 60 minutes
Study: 19494795
Drug: NGX-4010 capsaicin
Normalized name: Capsaicin
DrugBank: Capsaicin (DB06774)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: NGX-4010 capsaicin patch (640 microg/cm2) applied for 90 minutes
Study: 19494795
Drug: NGX-4010 capsaicin
Normalized name: Capsaicin
DrugBank: Capsaicin (DB06774)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: NGX-4010 capsaicin patch (640 microg/cm2) applied on feet
Study: 19494795
Drug: NGX-4010 capsaicin
Normalized name: Capsaicin
DrugBank: Capsaicin (DB06774)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: NGX-4010 capsaicin patch (640 microg/cm2) with larger treatment areas
Study: 17185118
Drug: Lidocaine with
Normalized name: Lidocaine with Tegaderm
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine with epinephrine (36 mg lidocaine + 18 mug epinephrine)
Study: 17185118
Drug: Lidocaine plus
Normalized name: Icy Hot Lidocaine Plus Menthol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine plus meperidine with epinephrine (36 mg lidocaine + 18 mug epinephrine + 36 mg meperidine + 18 mug epinephrine)
Study: 15794456
Drug: 18% carbamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: 18% carbamide peroxide paint-on gel
Study: 14700480
Drug: Oral bexarotene
Normalized name: Bexarotene
DrugBank: Bexarotene (DB00307)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Oral bexarotene 300 mg/m2/day
Study: 14700480
Drug: Oral bexarotene
Normalized name: Bexarotene
DrugBank: Bexarotene (DB00307)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Oral bexarotene 600 mg/m2/day
Study: 14700480
Drug: Placebo (prior
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (prior chemotherapy responders)
Study: 14700480
Drug: Oral bexarotene
Normalized name: Bexarotene
DrugBank: Bexarotene (DB00307)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Oral bexarotene 300 mg/m2/day (prior chemotherapy responders)
Study: 14700480
Drug: Oral bexarotene
Normalized name: Bexarotene
DrugBank: Bexarotene (DB00307)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Oral bexarotene 600 mg/m2/day (prior chemotherapy responders)
Study: 9643407
Drug: Postoperative adjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative adjuvant therapy (radiotherapy and/or systemic chemotherapy)
Study: 2789438
Drug: 15% polyvinylpyrrolidone
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15% polyvinylpyrrolidone (PVP) solution
Study: 2789438
Drug: 20% polyvinylpyrrolidone
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20% polyvinylpyrrolidone (PVP) solution
Study: 28339098
Drug: Chemotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy with concurrent cediranib and continued as maintenance
Study: 28339098
Drug: Standard chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard chemotherapy only
Study: 21060206
Drug: Erythropoietin (EPO)
Normalized name: Erythropoietin
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythropoietin (EPO) administration
Study: 21060206
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no EPO administration)
Study: 16604826
Drug: Letrozole (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Letrozole (2.5 mg daily for 5 days)